Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $31.43 million.

GUIDANCE:

Halozyme Therapeutics sees FY2018 revenue of $115-125 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.